A Study of AVZO-103 Alone or in Combination With Pembrolizumab in People With Solid Tumor Cancer

Full Title

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients with Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Gopa Iyer’s office at 646-888-4737.

Protocol

26-111

Phase

Phase I/II (phases 1 and 2 combined)

Investigator

Gopa Iyer

Co-Investigators

Komal Jhaveri

Diseases

Breast Cancer
Genitourinary Cancer › Bladder Cancer
Gynecologic Cancer › Cervical Cancer
Lung Cancer › Lung Cancer, Non-Small Cell
Solid Tumors

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07193511

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description